Cryoport reports first quarter 2025 financial results

Commercial cell & gene therapy revenue of $7.2 million, up 33% year over year q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year supporting 711 global clinical trials as of march 31, 2025 strategic partnership with dhl; cryopdp divestiture expected to close q2/q3 2025 nashville, tenn. , may 7, 2025 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) (cryoport), a global provider of temperature-controlled supply chain solutions for the life sciences sector, today announced financial results for the first quarter (q1) ended march 31, 2025.
CYRX Ratings Summary
CYRX Quant Ranking